metronidazole

(redirected from acea)
Also found in: Dictionary, Thesaurus, Acronyms.

metronidazole

 [mĕ″tro-nid´ah-zōl]
an antibacterial and antiprotozoal agent effective against obligate anaerobes; used as the base, administered orally and intravaginally in Trichomonas vaginalis infection in females and orally in T. vaginalis infection in males and in intestinal amebiasis. It is used orally or intravenously in extraintestinal amebiasis and infection by obligate anaerobic bacteria and intravenously for the prophylaxis of colonic perioperative infection. It is also used topically in the treatment of rosacea. The hydrochloride salt is administered intravenously for the same indications for which the base is used intravenously.

metronidazole

Acea (UK), Anabact (UK), Apo-Metronidazole (CA), Elyzol (UK), Flagyl, Flagyl ER, Flagystatin (CA), Florazole ER, MetroCream, MetroGel, MetroGel-Vaginal, MetroLotion, Metrolyl (UK), Metrosa (UK), Metrotop, Metrozol (UK), Neutratop (UK), Nidagel (CA), Noritate, Novo-Nidazol (CA), PMS-Metronidazole (CA), Rosasol (CA), Rozex, Zidoval (UK), Zyomet (UK)

metronidazole hydrochloride

Flagyl IV

Pharmacologic class: Nitroimidazole derivative

Therapeutic class: Anti-infective, antiprotozoal

Pregnancy risk category B

FDA Box Warning

• Drug is carcinogenic in mice and rats. Avoid unnecessary use; reserve drug for indicated conditions.

Action

Disturbs DNA synthesis in susceptible bacterial organisms

Availability

Capsules: 375 mg

Powder for injection: 5 mg/ml, 500-mg vials

Premixed injection: 500 mg/100 ml

Tablets: 250 mg, 500 mg

Tablets (extended-release): 750 mg

Topical cream, topical gel: 0.75% in 28.4-g tubes

Topical lotion: 0.75% in 59-ml bottle

Vaginal gel: 0.75% (37.5 mg/5-g applicator) in 70-g tubes

Indications and dosages

Trichomoniasis

Adults: 2 g P.O. as a single dose or in two 1-g doses given on same day. Alternatively, 500 mg P.O. b.i.d. for 7 days.

Bacterial infections

Adults: Initially, 15 mg/kg I.V., followed by 7.5 mg/kg I.V. q 6 hours, not to exceed 4 g/day for 7 to 10 days

Amebiasis

Adults: 750 mg P.O. q 8 hours for 5 to 10 days

Amebic liver abscess

Adults: 500 to 750 mg P.O. t.i.d. for 5 to 10 days. If drug can't be given orally, administer 500 mg I.V. q 6 hours for 10 days.

Children: 35 to 50 mg/kg/day P.O. in three divided doses for 10 days, to a maximum of 750 mg/dose

Bacterial vaginosis

Adults: In nonpregnant patients, 750 mg/day P.O. (extended-release) for 7 days or 5 g of 0.75% vaginal gel b.i.d. for 5 days. In pregnant patients, 250 mg P.O. t.i.d. for 7 days.

Perioperative prophylaxis in colorectal surgery

Adults: Initially, 15 mg/kg I.V. infusion over 30 to 60 minutes, completed 1 hour before surgery; if necessary, 7.5 mg/kg I.V. infusion over 30 to 60 minutes at 6 and 12 hours after initial dose

Rosacea

Adults: Rub a thin layer of topical lotion, gel, or cream onto entire affected area morning and evening. Improvement should occur within 3 weeks.

Contraindications

• Hypersensitivity to drug, other nitroimidazole derivatives, or parabens (topical form only)

• First-trimester pregnancy in patients with trichomoniasis

Precautions

Use cautiously in:

• severe hepatic impairment

• history of blood dyscrasias, seizures, or other neurologic problems

• breastfeeding patients

• children.

Administration

• Reconstitute powder for injection by adding 4.4 ml of sterile or bacteriostatic water for injection, 0.9% sodium chloride injection, or bacteriostatic sodium chloride injection to 500-mg vial. Further dilute resulting

concentration (100 mg/ml) in 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer's injection solution to a concentration of 8 mg/ml or less. Infuse each I.V. dose over 1 hour.

• Be aware that for I.V. injection, drug need not be diluted or neutralized.

• Don't use equipment containing aluminum to reconstitute or transfer reconstituted solution to diluent; solution may turn reddish-brown.

• Don't interchange vaginal gel with topical gel, cream, or lotion.

Adverse reactions

CNS: dizziness, headache, ataxia, vertigo, incoordination, insomnia, fatigue

EENT: rhinitis, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, abdominal pain, furry tongue, glossitis, dry mouth, anorexia

GU: dysuria, dark urine, incontinence

Hematologic: leukopenia

Skin: rash, urticaria, burning, mild skin dryness, skin irritation, transient redness (with topical forms)

Other: unpleasant or metallic taste, superinfection, phlebitis at I.V. site

Interactions

Drug-drug. Azathioprine, fluorouracil: increased risk of leukopenia

Cimetidine: decreased metronidazole metabolism, increased risk of toxicity

Disulfiram: acute psychosis and confusion

Lithium: increased lithium blood level

Phenobarbital: increased metronidazole metabolism, decreased efficacy

Warfarin: increased warfarin effects

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase: altered levels

Drug-behaviors. Alcohol use: disulfiram-like reaction

Patient monitoring

• Monitor I.V. site. Avoid prolonged use of indwelling catheter.

• Evaluate hematologic studies, especially in patients with history of blood dyscrasias.

Patient teaching

• Advise patient to take drug with food if it causes GI upset. However, instruct him to take extended-release tablets 1 hour before or 2 hours after meals.

• Tell patient with trichomoniasis to refrain from sexual intercourse or to have male partner wear a condom to prevent reinfection. Explain that asymptomatic sex partners should be treated simultaneously.

• Advise patient to report fever, sore throat, bleeding, or bruising.

• Inform patient that drug may cause metallic taste and may discolor urine deep brownish-red.

• Tell patient using topical form to clean area thoroughly with mild cleanser before use and then wait 15 to 20 minutes before applying drug. Tell her she may apply cosmetics to skin after applying drug; with topical lotion, instruct her to let skin dry at least 5 minutes before applying cosmetics.

• Tell female patient to consult prescriber if she is pregnant or plans to become pregnant.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

metronidazole

(mĕt′rə-nī′də-zōl′)
n.
A synthetic antimicrobial drug, C6H9N3O3, used to treat vaginal trichomoniasis, anaerobic bacterial infections, and intestinal amebiasis.

metronidazole

Noritate® Dermatology An antibiotic used for managing dermatitides and erythema of rosacea. See Rosacea Infectious disease An antibiotic used to treat bacterial, fungal, and parasitic infections; it is the most effective agent for H pylori infections.

metronidazole

An antibiotic drug effective against Trichomonas vaginalis and Entamoeba histolytica as well as many other organisms. It is especially useful in the treatment of amoebic dysentery and amoebic liver abscesses as well as ANAEROBIC infections. The drug is on the WHO official list. Brand names are Acea Gel, Elyzol, Flagyl, Metrosa and Zidoval. The drug is also formulated with the antifungal drug nystatin under the brand name Flagyl Compak and, for external use only, under the brand names Anabact, Metrogel, Metrotop and Rozex.

Metronidazole

An anti-infective agent regarded as the best available drug for treating trichomoniasis. It is sold under the trade names Flagyl and MetroGel.
Mentioned in: Trichomoniasis
References in periodicals archive ?
Both ACEA and Agilent are reputed to be scientific and technical innovators, building systems and products of exceptional quality.
Business Plan Foresees Higher Capex: The updated business plan 2018-2022 presented in November 2017 confirmed Acea's focus on regulated businesses, increasing the overall capex foreseen across the period (EUR3.1 billion in 2018-2022 against EUR2.4 billion in the previous 2016-2020 plan).
According to ACEA's calculations, Spain recorded the largest increase in alternative fuel vehicle registrations (+87.4 percent), followed by Germany (+67.5) percent.
- AceA has been granted 40,000,000 options (AceA Options), entitling AceA to subscribe for an aggregate 40,000,000 new ordinary shares (Option Shares) in the capital of Gossan Hill at
The third recommendation of ACEA is to reduce the regulatory burden and the cost of doing business in Europe by systematically carrying out competitiveness proofing and impact assessment for each new piece of legislation.
The ACEA also rejects the gradual elimination of "super credits" (bonuses given for manufacturing green cars).
8 December 2011 -- Standard & Poor's on Wednesday downgraded its long-term and short-term corporate credit ratings on Italian multiutility Acea (BIT:ACE) to A-/A-2 from A/A-1, citing deteriorating financial ratios.
The systems will be installed at Raffineria, an ACEA substation in Rome, and are expected to provide an integrated solution for generating, storing and delivering electricity to charge EVs.
Electronics company Toshiba Corporation (TOKYO:6502) announced on Monday that its Italian power systems subsidiary Ansaldo Transmissione & Distribuzione SpA has won a contract to supply a key element of a smart grid system to Rome-based public utility ACEA Distribuzione SpA.
Sales of new passenger cars in the European Union fell 1.4 percent year-on-year in January, industry association ACEA said on Wednesday.
European Automobile Manufacturers' Association (ACEA) said that car registrations dropped by 16.6 percent in October 2010.
6 October 2010 - US ACEA Biosciences Inc and Vivo Biosciences Inc said today they have started collaboration for the further development of label-free and real-time cell based assays for the xCELLigence System, which is co-developed by Swiss Roche (VTX: ROG) and ACEA and marketed by Roche Applied Science.